Boehringer Ingelheim Advances First-in-Class IL-11 Inhibitor BI 765423 to Phase II Trial for Idiopathic Pulmonary Fibrosis
Key Insights
Boehringer Ingelheim has initiated a Phase IIa clinical trial for BI 765423, a novel monoclonal antibody targeting interleukin-11 (IL-11) in patients with idiopathic pulmonary fibrosis (search).
The first-in-class IL-11 inhibitor aims to go beyond current treatments by potentially restoring lung functionality rather than just slowing disease progression.
Pre-clinical studies demonstrated that anti-IL-11 treatment can halt fibrosis (search) and restore barrier function, resulting in improved lung function and tissue integrity.
Boehringer Ingelheim announced the initiation of a Phase IIa clinical trial evaluating BI 765423, a novel monoclonal antibody targeting interleukin-11 (IL-11), in patients with idiopathic pulmonary fibrosis (search) (IPF (search)). This marks the first efficacy study for the potential first-in-class IL-11 inhibitor, representing a significant milestone in the company's commitment to advancing care for progressive fibrotic lung diseases.
Addressing Critical Unmet Medical Need
IPF (search) affects over three million people worldwide and presents a devastating prognosis. The progressive, life-shortening lung disease causes worsening breathlessness and declining lung function in most patients. With a five-year survival rate lower than prostate cancer, female breast cancer, and colon cancer, IPF substantially impacts quality of life, with half of patients succumbing to the disease within five years of diagnosis.
Current medicines can slow disease progression but cannot fully halt lung function decline or reverse lung scarring, creating a high unmet need for treatments that can stop disease progression or reverse IPF (search) effects.
Novel Mechanism of Action
BI 765423 targets IL-11, a key driver of fibrosis (search) across multiple organs. The monoclonal antibody is designed to bind directly to IL-11, blocking its interaction with its receptor and thereby interrupting the signaling pathways that cause fibrosis.
"With BI 765423, we aim to go beyond slowing disease and to pursue next generation therapies that could restore lung functionality for people living with IPF (search)," said Vittoria Zinzalla, Global Head of Experimental Medicine at Boehringer Ingelheim. "Our aim is to transform the lives of patients and their families by demonstrating the potential of this first-in-class IL-11 inhibitor to deliver clear benefits for patients, backed by compelling evidence and delivered at speed."
Promising Pre-clinical Evidence
Pre-clinical studies have demonstrated that anti-IL-11 treatment can halt fibrosis (search) and restore barrier function, resulting in improved lung function and tissue integrity. By targeting this mechanism, BI 765423 aims not only to slow lung damage but also to help restore lung functionality.
Clinical Development Progress
In Phase I studies, BI 765423 showed a favorable safety and tolerability profile in healthy volunteers across a wide dose range. The Phase IIa study represents the first evaluation of the drug's efficacy in IPF (search) patients.
The compound is an acquired asset from Enleofen (search) with in-licensed intellectual property from Singapore Health Services and the National University of Singapore.
Company's IPF Portfolio
Boehringer Ingelheim maintains a long-standing commitment to advancing care in pulmonary fibrosis (search). The company was recently granted FDA approval for JASCAYD (search)®, marking the first new treatment option in IPF (search) in a decade, demonstrating its continued focus on addressing this challenging disease area.